Illicit online pharmacies selling counterfeit drugs in a global virtual marketplace remain a critical problem in global health. Yet they continue to operate with little regulation while growing numbers of consumers access the Internet for health inform…

The global drug supply chain has resulted in tremendous vulnerabilities. Despite individual country efforts, both developed and resource-poor countries have experienced tremendous challenges with ensuring safety of the drug supply. In this piece, the f…

Despite some law enforcement successes, organizations engaged in counterfeiting continued manufacturing, distributing and selling a wide range of unsafe medicines during the past year. This article will identify some of these successes that were made p…

Many potentially useful medicines arise from developing countries’ biodiverse environments as well as from indigenous community knowledge. This bioprospecting has become an important strategy in drug discovery and development. However, global intelle…

We describe a new trust-based global health security initiative known as CORDS: Connecting Organizations for Regional Disease Surveillance. Initiated and managed by the Nuclear Threat Initiative with support of The Rockefeller Foundation, Fondation Mé…

Global health issues that transcend geopolitical borders are altering the nature of global health governance. Sovereign nations are more connected than ever and increasingly exposed to trans-border health risks. Traditional global health governance may…

This issue of the Journal of Commercial Biotechnology includes the papers from the seventh Annual San Diego Health Policy Conference, ‘Public–Private Partnerships in Global Health’, held on 25 March 2011. The San Diego Heath Policy Conference is …

The Journal of Commercial Biotechnology has been acquired by thinkBiotech LLC and is now hosted at www.CommercialBiotechnology.com .

The August 2011 issue of the Journal of Commercial Biotechnology is now available. The links below will take you to

An early-stage CNS therapeutic company on whose board I sit is looking for investments in the UK or the United